Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada And Richter Launch Teriparatide Across Europe Following Forsteo Expiry

Executive Summary

Stada and Gedeon Richter have launched their respective Movymia and Terrosa teriparatide biosimilars in Europe, with Stada eyeing 24 individual countries.

You may also be interested in...



Pfenex And Alvogen Forsteo Biosimilars Primed For EU Market

Shortly after announcing the launch of Bonsity (teriparatide) in the US, Pfenex and Alvogen have picked up positive opinions from the EMA’s CHMP for their teriparatide biosimilar. However, Accord Healthcare has withdrawn its own application following concerns raised by the agency.

Stada Says Teriparatide Roll-Out Has Been Successful

Seven months after introducing its teriparatide biosimilar to Eli Lily’s Forsteo into many European markets, Stada is pleased with results and says doctors and patients alike have responded well.

Bortezomib Booms For Stada As Russian Problem Remains

With group sales rising by double digits in 2019, Stada says it has the firepower to accelerate investment not only in the firm’s own product development but also broadly into external co-development and product in-licensing, to support sustainability and long-term growth.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel